Revolution Medicines' Pill Doubles Pancreatic Cancer Survival
Revolution Medicines announced Phase 3 data showing daraxonrasib extended median survival to 13.2 months in advanced pancreatic adenocarcinoma versus 6.7 months on standard chemotherapy. The near-doubling of survival in one of oncology's hardest-to-treat cancers positions Revolution for an FDA approval filing. No